Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The study is testing the hypothesis, that the application of low dose erythropoetin beta (35
I.E./kg BW/week) for 6 months following successful coronary revascularization by PCI improves
left ventricular remodeling as assessed by cardiac MRI.